Clinical trial
Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's…
NCT00003245 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003245 |
|---|---|
| Title | Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma |
| Official title | Phase II Study of Irinotecan for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | irinotecan hydrochloride |
| Enrollment | 50 |
| Start date | Feb 18, 1998 |
| Primary completion | Jul 30, 2004 |
| Completion | Jul 30, 2004 |
| First posted | Sep 24, 2003 |
| Last update posted | Nov 15, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: